D. Boral Capital analyst Jason Kolbert lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $8 from $15 and keeps a Buy rating on the shares following the Q4 report. The firm cites the “depressed valuation” of the stock and the company’s need for capital for the target cut. However, it still believes in the therapeutic potential of brilaroxazine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH: